Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding study of LOU064 in adults with chronic spontaneous urticaria inadequately controlled by H1-antihistamines
NL-OMON48501Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of remibrutinib in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in UAS7 at Week 4. Started Jan 2020; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON48501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48501.